1. The addition of neratinib to standard therapy was more likely to result in higher pathological complete response rates compared...

1. The addition of veliparib-carboplatin to standard therapy in treating triple-negative breast cancer patients showed higher rates of pathological complete...

1. Using immune checkpoint blockade, this phase 2 study showed favourable complete and partial response rates, and increased progression free...

1. The use of interim PET-CT scanning can de-escalate chemotherapy use during treatment for advanced Hodgkin’s disease by using doxorubicin,...

  1. Adding the proteasome inhibitor Ixazomib to lenalidomide and dexamethasone significantly increased progression-free survival compared to lenalidomide and dexamethasone...

1. In grade 2 glioma patients younger than 40 years old that have undergone subtotal tumour resection, or in patients...

1. The overall survival rate for advanced head and neck (H&N) cancer patients undergoing PET-CT guided surveillance was similar to...

  1. A weekly dosing regimen of Paclitaxel versus the standard dosing of Paclitaxel every 3 weeks, both administered with...

  1. The expression status of biomarker CDX2 was identified as an independent prognosticator in stage II and III colon...

  1. The risk of a second solid cancer following treatment for Hodgkin’s Lymphoma (HL) did not change significantly between...